Compliance with national guidelines for the management of drug-drug interactions in dutch community pharmacies

被引:15
|
作者
Buurma, Henk
Schalekamp, Tom
Egberts, Antoine C. G.
De Smet, Peter A. G. M.
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands
[3] St Elizabeth Hosp, Tilburg, Netherlands
[4] TweeSteden Hosp, Hosp Pharm Midden Brabant, Tilburg, Netherlands
[5] Sci Inst Dutch Pharmacists, The Hague, Netherlands
[6] Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
关键词
compliance; drug-drug interaction; drug related problem; guideline; intervention; pharmaceutical care; pharmacist; risk management;
D O I
10.1345/aph.1K240
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Pharmacists contribute to the detection and prevention of drug therapy-related problems, including drug-drug interactions. Little is known about compliance with pharmacy practice guidelines for the management of drug-drug interaction alerts. OBJECTIVE: To measure the compliance of community pharmacists with Dutch guidelines for the management of drug-drug interactions and to determine patient- and prescriber-related determinants for noncompliance. METHODS: Sixteen clinically relevant drug-drug interactions were included in the study based on certain described criteria. From June to August 2005, Dutch pharmacists (N = 149) collected alerts occurring in daily patient care for these interactions as well as information related to the patient, the alert itself, the prescriber, and the management of the alert. Noncompliance was measured by comparing the management executed by the pharmacy with the national guidelines. RESULTS: Overall compliance with the guidelines was 69.3% (n = 423), with large differences between the various drug-drug interactions. Male sex (OR 2.25; 95% CI 1.52 to 3.31), oldest age (> 75 y; ORA.97; 95% CI 1.03 to 3.75), and polypharmacy (> 7 medications; OR 2.35; 95% CI 1.46 to 3.80) were associated with a higher probability for noncompliance with the guidelines. Prescriber-related variables had no significant influence on guideline compliance. Substitution of one of the involved agents, recommended for most of the drug-drug interactions, was executed in a small minority of cases. The outcome of interaction management, such as substitution, dose reduction, or temporary stop of one of the agents, was frequently inconsistent with the guidelines. Compliance rates were partly influenced by the ultimate decision made by the prescriber. In that way, pharmacies' compliance was not solely assessed. However, in only 22.5% of the cases was the drug-drug interaction presented to the prescriber. CONCLUSIONS: Noncompliance with Dutch guidelines for the management of drug-drug interaction alerts is common in community pharmacies. Further research into underlying reasons for noncompliance is warranted, such as the relation between pharmacist and prescriber in this context.
引用
收藏
页码:2024 / 2031
页数:8
相关论文
共 50 条
  • [1] Adherence to a guideline for the management of drug-drug interactions in Dutch community pharmacies
    Buurma, Henk
    Schalekamp, Tom
    Egberts, Toine C. G.
    De Smet, Peter A. G.
    [J]. PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 665 - 665
  • [2] Clinical risk management in Dutch community pharmacies - The case of drug-drug interactions
    Buurma, Henk
    De Smet, Peter A. G. M.
    Egberts, Antoine C. G.
    [J]. DRUG SAFETY, 2006, 29 (08) : 723 - 732
  • [3] The occurrence and handling of drug-drug interactions in Dutch community pharmacies
    Buurma, Henk
    De Smet, Peter A. G. M.
    Kruijtbosch, Martine
    Egberts, Antoine C.
    [J]. PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 438 - 438
  • [4] Drug-drug interaction management in German community pharmacies
    Braun, C. A.
    Woltersdorf, R.
    Simons, S.
    Klahn, D.
    Jaehde, U.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 495 - 496
  • [5] Clinical Risk Management in Dutch Community PharmaciesThe Case of Drug-Drug Interactions
    Henk Buurma
    Peter A.G.M De Smet
    Antoine C.G. Egberts
    [J]. Drug Safety, 2006, 29 : 723 - 732
  • [6] Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece
    Chatsisvili, Anna
    Sapounidis, Ioakeim
    Pavlidou, Georgia
    Zoumpouridou, Eudoxia
    Karakousis, Vasileios-Alexandros
    Spanakis, Marios
    Teperikidis, Lefteris
    Niopas, Ioannis
    [J]. PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 187 - 193
  • [7] Warnings for drug-drug interactions in consumer medication information provided by community pharmacies
    Panich, Jennifer
    Gooden, Andrea
    Shirazi, F. Mazda
    Malone, Daniel C.
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2019, 59 (01) : 35 - 42
  • [8] A study of potential drug-drug interactions in prescriptions received at selected community pharmacies
    Ramesh, Adepu
    Singhal, Rohit
    Nagavi, B. G.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2008, 42 (02) : 184 - 189
  • [9] Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants: an intervention study in community pharmacies
    Capiau, Andreas
    Mehuys, Els
    Grymonprez, Maxim
    Van Tongelen, Inge
    Christiaens, Thierry
    Tommelein, Eline
    Philippe, Genevieve
    Lahousse, Lies
    De Backer, Tine
    Boussery, Koen
    [J]. THROMBOSIS RESEARCH, 2024, 238 : 223 - 231
  • [10] Initiation of a drug-drug interaction register for community pharmacies
    Braun, C. A.
    van Boemmel-Wegmann, S.
    Simons, S.
    Diederichs, L.
    Wuelfing, M.
    Schummer, B.
    Koenig, F. G.
    Schwalbe, O.
    Jaehde, U.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (03) : 498 - 498